Esperion Therapeutics Inc

We remain bullish across all horizons as ESPR sits in a Stage 2 advance with a fresh higher-high/higher-low structure driven by a Lockout Rally above rising EMAs. The active Lockout Rally override validates a Buy Now posture despite near-term extension, favoring participation on shallow retracements into the 9/20 EMA support zone. Moderate distribution risk exists as EMAs flatten near recent highs, warranting vigilance for a shift in momentum.

• ↑Q3 revenue +69% YoY to $87.3M
• ↑U.S. net product revenue $40.7M, up 31% YoY
• ↓Earnings yield remains negative and profitability weak